MY193754A - Treatment for parkinson's disease - Google Patents

Treatment for parkinson's disease

Info

Publication number
MY193754A
MY193754A MYPI2018002187A MYPI2018002187A MY193754A MY 193754 A MY193754 A MY 193754A MY PI2018002187 A MYPI2018002187 A MY PI2018002187A MY PI2018002187 A MYPI2018002187 A MY PI2018002187A MY 193754 A MY193754 A MY 193754A
Authority
MY
Malaysia
Prior art keywords
alkyl
haloalkyl
hydrogen
disease
parkinson
Prior art date
Application number
MYPI2018002187A
Other languages
English (en)
Inventor
Krishnaji Damle Nitin
Nandlalji Mandhane Sanjay
Atmaramji UPADHYA Manoj
Vishwanath MEHETRE Sameer
Uttamrao CHIDREWAR Gajanan
Sengupta Prabal
Rao Chitturi Trinadha
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MY193754A publication Critical patent/MY193754A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2018002187A 2016-06-02 2017-06-02 Treatment for parkinson's disease MY193754A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
MY193754A true MY193754A (en) 2022-10-27

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018002187A MY193754A (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Country Status (27)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CA (1) CA3024976A1 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
KR102508288B1 (ko) 2016-06-02 2023-03-09 썬 파마 어드밴스트 리서치 컴패니 리미티드 파킨슨병의 치료
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMAL STORAGE DISORDERS
KR20220024463A (ko) * 2019-06-11 2022-03-03 썬 파마 어드밴스트 리서치 컴패니 리미티드 시뉴클레인병증에 대한 치료
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
AU2021317186A1 (en) 2020-07-31 2023-03-16 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease
US20250275953A1 (en) 2022-05-02 2025-09-04 Sun Pharma Advanced Research Company Ltd. Vodobatinib for reducing progression of parkinson's disease
WO2025058473A1 (ko) 2023-09-14 2025-03-20 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012208388C1 (en) * 2011-01-21 2017-04-27 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
MX2017014752A (es) * 2015-05-18 2018-03-23 Sun Pharma Advanced Res Co Ltd Nuevos etinos de amidoheteroaril aroil hidrazida.
KR102508288B1 (ko) * 2016-06-02 2023-03-09 썬 파마 어드밴스트 리서치 컴패니 리미티드 파킨슨병의 치료

Also Published As

Publication number Publication date
DK3463351T3 (da) 2022-06-07
US20240066014A1 (en) 2024-02-29
MX2018014944A (es) 2019-03-07
CN109475539A (zh) 2019-03-15
PL3463351T3 (pl) 2022-06-20
WO2017208267A1 (en) 2017-12-07
US20210015805A1 (en) 2021-01-21
EP3463351B1 (en) 2022-04-27
SI3463351T1 (sl) 2022-07-29
BR112018074439A2 (pt) 2019-03-06
RS63243B1 (sr) 2022-06-30
NZ748592A (en) 2025-11-28
UA123018C2 (uk) 2021-02-03
CL2018003431A1 (es) 2019-05-10
AU2017273415A1 (en) 2018-12-06
PT3463351T (pt) 2022-06-02
US20190275017A1 (en) 2019-09-12
LT3463351T (lt) 2022-06-10
US20220273632A1 (en) 2022-09-01
HUE059387T2 (hu) 2022-11-28
ES2914782T3 (es) 2022-06-16
SMT202200228T1 (it) 2022-07-21
MX385276B (es) 2025-03-18
PH12018502457B1 (en) 2022-01-12
EP4085912A1 (en) 2022-11-09
US10849887B2 (en) 2020-12-01
PH12018502457A1 (en) 2019-10-21
IL263188B (en) 2021-08-31
EP3463351A1 (en) 2019-04-10
KR20190015257A (ko) 2019-02-13
IL263188A (en) 2018-12-31
SG11201810294QA (en) 2018-12-28
CN109475539B (zh) 2021-12-28
US11583522B2 (en) 2023-02-21
US11813252B2 (en) 2023-11-14
CA3024976A1 (en) 2017-12-07
HRP20220683T1 (hr) 2022-07-08
CY1125285T1 (el) 2025-03-28
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
KR102508288B1 (ko) 2023-03-09
JP6974357B2 (ja) 2021-12-01

Similar Documents

Publication Publication Date Title
PH12018502457B1 (en) Treatment for parkinson's disease
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201700077A1 (ru) Соединения аминопиримидинила в качестве ингибиторов jak
MX386258B (es) Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
EA201790713A1 (ru) N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
AU2018253590A1 (en) Imidazopyridazine compounds
MX2020013099A (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
IN2015DN00837A (enExample)
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MY170262A (en) Dicarboxylic acid compound